Myriad Genetics Statistics
Total Valuation
MYGN has a market cap or net worth of $2.35 billion. The enterprise value is $2.39 billion.
| Market Cap | 2.35B |
| Enterprise Value | 2.39B |
Important Dates
The next estimated earnings date is Thursday, August 1, 2024, after market close.
| Earnings Date | Aug 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MYGN has 90.51 million shares outstanding. The number of shares has increased by 10.58% in one year.
| Shares Outstanding | 90.51M |
| Shares Change (YoY) | +10.58% |
| Shares Change (QoQ) | +4.05% |
| Owned by Insiders (%) | 2.18% |
| Owned by Institutions (%) | 105.77% |
| Float | 71.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 352.15 |
| PS Ratio | 3.04 |
| Forward PS | 2.74 |
| PB Ratio | 3.09 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.40 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.99, with a Debt / Equity ratio of 0.19.
| Current Ratio | 1.99 |
| Quick Ratio | 1.52 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -80.21 |
Financial Efficiency
Return on equity (ROE) is -31.70% and return on invested capital (ROIC) is -25.71%.
| Return on Equity (ROE) | -31.70% |
| Return on Assets (ROA) | -20.40% |
| Return on Capital (ROIC) | -25.71% |
| Revenue Per Employee | $286,741 |
| Profits Per Employee | -$86,889 |
| Employee Count | 2,700 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 10.41 |
Taxes
| Income Tax | -900,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +15.83% in the last 52 weeks. The beta is 1.96, so MYGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.96 |
| 52-Week Price Change | +15.83% |
| 50-Day Moving Average | 24.32 |
| 200-Day Moving Average | 20.64 |
| Relative Strength Index (RSI) | 58.72 |
| Average Volume (20 Days) | 844,561 |
Short Selling Information
The latest short interest is 4.61 million, so 5.10% of the outstanding shares have been sold short.
| Short Interest | 4.61M |
| Short Previous Month | 6.09M |
| Short % of Shares Out | 5.10% |
| Short % of Float | 6.47% |
| Short Ratio (days to cover) | 5.76 |
Income Statement
In the last 12 months, MYGN had revenue of $774.20 million and -$234.60 million in losses. Loss per share was -$2.80.
| Revenue | 774.20M |
| Gross Profit | 532.60M |
| Operating Income | -233.10M |
| Pretax Income | -235.50M |
| Net Income | -234.60M |
| EBITDA | -163.70M |
| EBIT | -232.60M |
| Loss Per Share | -$2.80 |
Balance Sheet
The company has $104.30 million in cash and $146.80 million in debt, giving a net cash position of -$42.50 million or -$0.47 per share.
| Cash & Cash Equivalents | 104.30M |
| Total Debt | 146.80M |
| Net Cash | -42.50M |
| Net Cash Per Share | -$0.47 |
| Equity (Book Value) | 760.00M |
| Book Value Per Share | 8.40 |
| Working Capital | 144.20M |
Cash Flow
In the last 12 months, operating cash flow was -$96.30 million and capital expenditures -$58.40 million, giving a free cash flow of -$154.70 million.
| Operating Cash Flow | -96.30M |
| Capital Expenditures | -58.40M |
| Free Cash Flow | -154.70M |
| FCF Per Share | -$1.72 |
Margins
Gross margin is 68.79%, with operating and profit margins of -30.11% and -30.30%.
| Gross Margin | 68.79% |
| Operating Margin | -30.11% |
| Pretax Margin | -30.42% |
| Profit Margin | -30.30% |
| EBITDA Margin | -21.14% |
| EBIT Margin | -30.04% |
| FCF Margin | -19.98% |
Dividends & Yields
MYGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.58% |
| Shareholder Yield | -10.58% |
| Earnings Yield | -9.98% |
| FCF Yield | -6.58% |
Analyst Forecast
The average price target for MYGN is $25.00, which is -3.74% lower than the current price. The consensus rating is "Buy".
| Price Target | $25.00 |
| Price Target Difference | -3.74% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 7.51% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on March 26, 2009. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 26, 2009 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
MYGN has an Altman Z-Score of 3.36 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.36 |
| Piotroski F-Score | 4 |